Antibiotic Dosing in Pediatric Intensive Care

N/ARecruitingNCT02456974

University Hospital, Ghent640 enrolled

Overview

Pharmacokinetics of antibiotics in critically ill neonates, infants and children

Study Type

OBSERVATIONAL

Enrollment

640

Conditions

Pharmacokinetics Amoxicillin-clavulanate Piperacillin-tazobactam Vancomycin Teicoplanin Meropenem Ciprofloxacin Amikacin

Interventions

blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical carePROCEDURE

blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.PROCEDURE

blood sampling in patients receiving vancomycin as part of routine clinical care.PROCEDURE

Eligibility

Sex: ALLMin age: 1 DayMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients admitted to the pediatric intensive care unit * patient age/weight : 1,8 kg-15 years * patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines * intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred) Exclusion Criteria: * no catheter in place for blood sampling * absence of parental/patient consent * known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides * extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )

Locations (1)

Ghent University Hospital, Hospital Pharmacy

Ghent, Belgium

RECRUITING

Outcomes

Primary Outcomes

To investigate if first-dose blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.

Time frame: 2 years (expected)

To investigate if steady-state blood concentrations with maximum antimicrobial activity are achieved with current dosing regimens.

Time frame: 2 years (expected)

Secondary Outcomes

To compare measured first-dose blood concentrations with predefined pharmacodynamic targets (Time above MIC)

Time frame: 2 years (expected)

To compare measured steady-state blood concentrations with predefined pharmacodynamic targets (Time above MIC)

Time frame: 2 years (expected)

Central Contacts

Pieter De Cock, PharmD

CONTACT

+32 9 332 29 69 pieter.decock@uzgent.be

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.